Unum Therapeutics Inc. (UMRX) Reports Q3 Loss of $0.34, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LITE
6. LYB
7. TFII
8. NVT
9. SPY
10. AAPL

Go back to Unum Therapeutics Inc. (UMRX) Reports Q3 Loss of $0.34, Revenues Miss

Unum Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update

November 12, 2018 4:01 PM EST

- ACTR707 in Combination with Rituximab Selected as Lead Product Candidate for Further Development in r/r NHL

- New Solid Tumors Technology Platform Revealed at SITC

- More Details on Solid Tumor Activities to be Discussed at Upcoming Investor Event

CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today reported financial results and provided a corporate update for the third quarter ended September 30, 2018 and recent... More